A paid advertorial distributed through Newswire in September 2026 examines NEOLISE Renewal, a prescription-dependent compounded peptide protocol marketed to adults over 30 for visible skin aging and hair thinning. The piece discloses up front that it is advertising rather than independent medical reporting and that a commission may be earned on purchases.

The protocol combines four peptides in one pre-mixed injectable vial: GHK-Cu, a copper tripeptide first isolated from human plasma in 1973; BPC-157, a synthetic peptide the brand describes as studied for blood-vessel formation; TB-500, also known as thymosin beta-4; and KPV, the three-amino-acid tail of alpha-MSH. The product page displays GHK-Cu 10mg, BPC-157 3mg, TB-500 3mg and KPV 3mg, though the advertorial says the public wording did not make clear whether those are per-vial totals or concentrations.

Four peptides, one vial

NEOLISE, operated by Omni Health Ventures Inc., says it does not prescribe, compound, dispense or ship medication itself. Independent providers and a pharmacy handle that, and the review says the specific identities of the medical group and the pharmacy were not located on the public pages checked in September 2026.

The site FAQ states that blood work is not required and that a provider evaluates health history through the intake questionnaire alone. The review notes that a brand policy of that kind does not establish that laboratory testing is unnecessary for any individual, and that a prescription step is not evidence a product has been approved.

The price is the full term

Plans are listed at $239 to $299 per month depending on term length, but billed once for the whole term: $897 for three months, $1,614 for six, $2,868 for twelve. These are not month-to-month subscriptions that can be dropped after one payment, and Terms of Use Section 12 caps Omni Health Ventures' own liability at $100.

Where the FDA actually stands

Compounded drugs are not FDA-approved as finished products, and the review says it identified no FDA approval for any of the four peptides as used here. In briefing materials for the July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting, FDA staff proposed that BPC-157, TB-500 and KPV not be added to the Section 503A Bulks List, citing gaps including chemical characterization, insufficient effectiveness evidence for the nominated indications, and immunogenicity risk for BPC-157.

The committee then voted to recommend inclusion of all three, but that recommendation was advisory and nonbinding. The review says it found no final FDA rule resolving their Bulks List status.

Bottom line

The most useful thing in this advertorial is what it declines to reproduce: the brand's comparative, mechanistic and quantified outcome claims arrived without checkable citations, so the figures were left out and labeled marketing language. Ingredient-level research at different doses, routes and in animal or cell models does not substantiate outcomes for a finished four-peptide injectable, and the regulatory question behind three of those four peptides is still open.